In March 2026, the American College of Cardiology and American Heart Association — joined by nine other leading medical societies — released the first comprehensive rewrite of the national cholesterol guidelines since 2018. The new document is no longer called a "cholesterol" guideline at all. It is now the Guideline on the Management of Dyslipidemia, and the name change is the story: we now understand that heart-attack and stroke risk is driven not by one number, but by a family of cholesterol-carrying particles — LDL, triglyceride-rich remnant particles, and lipoprotein(a).
The Big Idea: Earlier and Lower, for Longer
The central message of the new guideline can be summarized in five words: earlier and lower, for longer. Atherosclerosis is not an event that happens in your sixties — it is a slow, cumulative process driven by decades of exposure to cholesterol-carrying particles. The longer your arteries are exposed to elevated LDL, the more plaque accumulates. The guideline responds by pushing risk assessment earlier in life, setting lower cholesterol targets, and emphasizing that maintaining those targets over decades is what actually prevents heart attacks.
What Actually Changed
The headline changes for patients:
- Hard cholesterol targets are back. The 2018 guideline emphasized percentage reductions; the 2026 guideline restores specific number goals — as low as an LDL below 55 mg/dL for the highest-risk patients. If you've been told "your statin is working, don't worry about the number," that advice has officially changed.
- A once-in-a-lifetime Lp(a) test for every adult. Lipoprotein(a) is a genetically determined particle that most people have never had measured. The new guideline recommends every adult be tested at least once. (We cover this in depth in its own article.)
- A new risk calculator that looks 30 years ahead. The PREVENT equations replace the older 10-year-only calculator, adding a 30-year risk horizon that changes the conversation for adults in their 30s, 40s, and 50s.
- Coronary calcium scoring is elevated. CAC scoring now carries the guideline's strongest recommendation class for refining borderline decisions — including using a score of zero to reasonably defer medication in selected lower-risk patients.
- Five new medications since 2018 are incorporated — expanding options well beyond statins for patients who need more lowering or can't tolerate statin therapy.
- Screening starts in childhood. The guideline recommends universal lipid screening for children ages 9–11 — because lifetime exposure starts early, and inherited cholesterol disorders are far more common than most families realize.
Why the Change in Philosophy?
Two decades of genetic studies, imaging research, and randomized trials have converged on the same conclusion: LDL-lowering works, it works proportionally to how much and how long you lower it, and there is no meaningful threshold below which lowering stops helping. Patients who keep LDL low for decades — whether through genetics, lifestyle, or medication — have dramatically lower lifetime rates of heart attack and stroke. The guideline simply brings practice in line with that evidence.
What This Means for You
If you haven't had a full lipid assessment recently — or you've never had an Lp(a) test, an apoB measurement, or a calcium score — the new guideline is a good reason to revisit your numbers. At Cardiolucent, this is the core of what we do: a comprehensive cardiovascular risk assessment that includes advanced lipid testing interpreted personally by Dr. Kedan, with a prevention plan calibrated to the new targets — not the old ones.
Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia — a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, published in Circulation and the Journal of the American College of Cardiology, March 2026.